What pricing and reimbursement policies to use for off-patent biologicals in Europe? - Results from the second EBE biological medicines policy survey

GaBI Journal

Volumn 6, Issue 2, 2017, Pages 61-78

  Roediger, Alexander ^a   Freischem, Barbara ^b   Reiland, Jean Baptiste ^c  

^a Laboratoire MSD   (France)

^b European Biopharmaceutical Enterprises   (France)

^c SANOFI   (France)

Author keywords

Biological medicines; Biosimilars; Off patent market; Pricing and reimbursement policy

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CONTROLLED STUDY; DECISION MAKING; HEALTH CARE POLICY; NORWAY; PATENT; PROSPECTIVE PRICING; REIMBURSEMENT; SERBIA; SWITZERLAND; TURKEY (REPUBLIC);

EID: 85029619034     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2017.0602.014     Document Type: Article

References (29)

1. European Commission. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461. 2012 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
2. European Union. Eur-Lex. Treaty of the Functioning of the European Union, Art. 168(7); Official Journal (9.5.2008) C 115/47-199 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:12012E/TXT
3. Medicines for Europe (2016), The role of generic medicines in sustaining healthcare systems: A European perspective. [cited 2017 Mar 17]. Available from: http://www.medicinesforeurope.com/wp-content/uploads/2016/03/infographicims.pdf
4. European Commission. What I need to know about biosimilar medicines-information for patients. January 2017 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://ec.europa.eu/growth/tools-databases/newsroom/cf/itemdetail.cfm?item_id=9066.
5. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). EMA/837805/2011. 27 September 2012 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf].
6. IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines. The role of functioning biosimilar markets. March 2016 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf
7. European Medicines Agency. European public assessment reports [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125
8. European Commission. The impact on biosimilar competition on price, volume and market share-updated version 2016 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://ec.europa.eu/growth/toolsdatabases/newsroom/cf/itemdetail.cfm?item_id=8854&lang=en
9. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191-6.
10. European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. 23 October 2014 [homepage on the Internet]. [2017 Mar 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
11. European Medicines Agency. European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications. EMA/940451/2011. December 2015 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf
12. Mestre-Ferrandiz J, Towse A, Berdud M, Biosimilars: How can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609-16.
13. Garattini L, Curto A, van de Vooren K. Western European markets for biosimilar and generic drugs: worth differentiating. Eur J Health Econ. 2015;16(7):683.
14. De Block M. Biosimilaires: la Belgique doit combler son retard. 7 Janvier 2016 [home page on the Internet]. [cited 2017 Mar 17]. Available from: http://www.deblock.belgium.be/fr/%C2%AB-biosimilaires-la-belgique-doit-comblerson-retard-%C2%BB
15. FIMEA (2015), Interchangeability of Biosimilars-Position of Finnish Medicines Agency Fimea. [cited 2017 Mar 17]. Available from: https://www.fimea.fi/documents/542809/838272/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf
16. Paul Ehrlich Institut. Position des Paul-Ehrlich-Instituts zur Interchangeability von Biosimilars [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.pei.de/EN/medicinal-products/antibodies-immunoglobulins-fusion-proteins/monoclonal-antibodies/biosimilars/position-peiinterchangebility-biosimilars-content.html
17. CBG-MEB. Biosimilar medicines [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://english.cbg-meb.nl/human/for-healthcare-providers/contents/biosimilar-medicines
18. European Commission. What you need to know about biosimilar medicinal products. A consensus information document [homepage on the Internet]. [cited 2017 Mar 17]. Available from: ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native+&cd=1&hl=en&ct=clnk&gl=us.
19. European Biopharmaceutical Enterprises. What pricing and reimbursement policies to use for off-patent biologicals?-Results from the EBE 2014 biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(1):17-24. doi:10.5639/gabij.2015.0401.006
20. L'Agence nationale de sécurité du médicament et des produits de santé. L'ANSM publie une mise au point sur les médicaments biosimilaires-Point d'Information. 3 Mai 2016 [homepage on the Internet] [cited 2017 Mar 17].Available from: http://ansm.sante.fr/S-informer/Points-d-information-Pointsd-information/L-ANSM-publie-une-mise-au-point-sur-les-medicamentsbiosimilaires-Point-d-Information
21. European Biopharmaceutical Enterprises. EBE Position Paper on tendering of biologicals, including biosimilars. 21 May 2012 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://www.ebe-biopharma.eu/documents/3/22/EBE-Position-Paper-on-Tendering-of-Biologicals-including-Biosimilars.
22. Gesundheit österreich GmbH (GOEG), WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (2015), Glossary; [cited 2017 Mar 17]. Available from: http://whocc.goeg.at/.
23. Dylst P, Simoens S, Arnold G Vulto. Reference pricing systems in Europe: characteristics and consequences. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(3-4):127-31. doi:10.5639/gabij.2012.0103-4.028
24. European Federation of Pharmaceutical Industries and Associations. EFPIA launches robust principles to secure a competitive european off-patent biologic medicines market [homepage on the Internet]. [cited 2017 Mar 17]. Available from:http://www.efpia.eu/mediaroom/300/21/EFPIA-Launches-Robust-Principlesto-Secure-a-Competitive-European-Off-Patent-Biologic-Medicines-Market
25. Curto S, Ghislandi S, van de Vooren K, Duranti S, Garratini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy. 2014;116(2-3):182-7.
26. European Union. Directive 2011/24/EU of the European Parliament and the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:en:PDF
27. European Commission. Commission Implementing Directive 2012/52/EU of 20 December 2012 laying down measures to facilitate the recognition of medical prescriptions issued in another Member State [homepage on the Internet]. [cited 2017 Mar 17]. Available from: http://ec.europa.eu/health//sites/health/files/cross_border_care/docs/impl_directive_presciptions_2012_en.pdf
28. EU Clinical Trials Register. Clinical trials for eudract_number:2014-002056-40 [homepage on the Internet]. [cited 2017 Mar 17]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002056-40]
29. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016; 44(4):257-66.